Although most of the American-based cannabis companies trade over the counter (OTC), some marijuana firms are traded on the NASDAQ. Many investors prefer NASDAQ listed stocks to other exchanges because of their increased liquidity as well as tighter spreads.

Numerous marijuana companies have been listed on reputable U.S exchanges, reflecting the rapid expansion of the cannabis industry. NASDAQ was among the first electronic exchanges and has long been popular for its unique technology and biotechnology. Here are the top NASDAQ-listed marijuana stocks:

The cannabis industry, especially the field of marijuana and biotech, is now attracting the attention of most investors.

Cannabis-based products are being utilized for the treatment of pain as well as several other chronic, fibrotic, and inflammatory diseases.

Several companies are also creating cannabinoid drugs for autism spectrum disorders, epileptic disorders, schizophrenia, Tourette syndrome, amphetamine addiction, Prader-Willi Syndrome, and glioma.

Cara Therapeutics is a biotechnology company that’s focused on creating and commercializing new medical entities for the indications of chronic pain and pruritus. Though all of the company’s clinical-stage brands target opioid receptors, Cara is now conducting in-depth research on cannabinoid products for treating neuropathic pain.

Cronos is a reputable Canadian-based cannabis company. It owns and seeks to partner with other cannabis-related subsidiaries plus licensed producers. Towards the end of 2018, Marlboro Maker Altria declared its intentions to invest USD 1.8 billion in Cronos. And this hasn’t only provided Cronos with additional money to finance its continued growth but also with a well-established business partner with exceptional experience in the marketing of customer brands.

This is a biotech company that specializes in the production of medical marijuana drugs. The company’s cannabis biotech initiatives are primarily focused on Arena’s APD371. They develop state-of-the-art products that offer optimal safety, effectiveness, and reliability. Patients with chronic pain, epileptic disorders, or schizophrenia can rely on Arena’s marijuana-based products for treating their symptoms. Investing in such a company’s marijuana stocks can prove to be highly profitable in the long run.

Corbus is a cannabis-based biotech company. Their research and manufacturing revolve around cannabis drugs which seek to treat fibrotic, chronic and inflammatory diseases. Plus, they also strive to cover several other ailments soon.

Being a blank check company, Atlantic Alliance, is currently operating under a merger agreement with Kalyx Development. Kalyx is a high-tech real estate investment trust in the U.S regulated cannabis industry.

GW Pharmaceutical is now devising a portfolio of cannabinoid medications. These include Sativex intended for the treatment of spasticity associated with multiple sclerosis (MS) and cancer pain. They also develop Epidiolex medicines, which are utilized for treating childhood epilepsy. Epidiolex was also approved by the FDA as a treatment option for the Lennox-Gastaut Syndrome and the Dravet Syndrome. Sativex, on the other hand, is commercialized in several countries outside the U.S and has received regulatory approval in numerous other nations.

Other indications show that the company is now developing cannabinoid products for schizophrenia, glioma, and autism spectrum disorders.

Being a clinical-stage biopharmaceutical firm, Intec Pharma develops drugs using its proprietary Accordion Pill technology. The company’s product pipeline incorporates cannabinoid-based drugs for treating fibromyalgia plus lower back pain.

Marrone develops and develops bio-based management as well as plant health products. And in the year 2017, the company announced that 3 MBII active ingredients are now permissible for use on cannabis crops.

This specialty pharmaceutical company develops innovative drugs as well as novel drug delivery systems. Though the Insys is popularly known for the production of Subsys fentanyl spray, it has also received FDA’s approval for synthetic THC, a dronabinol oral solution for treating nausea caused by anorexia as well as chemotherapy in patients with AIDS. Even more, the company is developing cannabinoid-based treatments for amphetamine addiction, epileptic disorders, and Prader-Willi Syndrome.

This company operates in the enforcement sector. It's business operations often support drug testing via hair samples. It’s widely known for developing unique cannabis-based products that are effective at treating several medical conditions, including pain, epilepsy, and arthritis.

New Age is a renowned manufacturer of beverages. Its products are derived from kombucha, yerba, green tea, as well as a mate. Over the past few months, the company has expanded its product offerings to include CBD infusions, bringing it into the sphere of cannabis stocks.

This specialty pharmaceutical company deals with the manufacturer of cannabinoid-based drugs. Their current pipeline includes products focused on the treatment of mild cognitive impairment as well as the Tourette syndrome. All the company’s products are safe, effective, and FDA-approved.

Tilray was among the first marijuana-related companies to have an IPO (initial public offering) in the U.S. Based in Nanaimo, Vancouver, the firm focuses on the development of medical cannabis products.

Village Farms only started trading on NASDAQ recently. The firm’s shares became available for traders on February 21, 2019. Though the company has many years of experience in greenhouse produce production, it has recently shifted its focus toward the production of cannabis.

Zynerba Pharmaceuticals specializes in the creation of synthetic cannabinoid treatments, which are often delivered through the skin (transdermal). Their pipeline currently involves two drugs being produced for conditions such as epilepsy, fibromyalgia, Fragile X syndrome, osteoarthritis, and peripheral neuropathic pain.

Over the past few years, the cannabis industry has witnessed tremendous changes. More and more companies are now developing and distributing medical marijuana products for the treatment of various ailments. From autism, glioma, schizophrenia, and Tourette syndrome to epileptic disorders, these products look set to bring relief to most patients.

If you’re an investor who’s looking to invest in marijuana stocks, you may want to consider partnering with the above companies. They’re professional, experienced, and highly reputable. Remember, the cannabis industry is quickly expanding and is ripe for investment. So, you can rest assured that investing in marijuana stocks will bring you substantial profits.